Form D/A
View Original Filing
Notice of Exempt Offering of Securities
Item 1. Issuer's Identity
Name of Issuer:
PRELUDE THERAPEUTICS INC
Jurisdiction of Incorporation/Organization
DELAWARE
Year of Incorporation/Organization
2016
Previous Name(s)
- PRELUDE THERAPEUTICS INC.
Item 2 Issuer Principal Place of Business and Contact Information
200 POWDER MILL ROAD
EXPERIMENTAL STATION E400/3213
WILMINGTON, DE 19803
Phone Number:
subscription required
Item 3. Related Persons
Name
KRISHNA VADDI
Address
subscription required
Relationship(s)
- EXECUTIVE OFFICER
- DIRECTOR
Clarification of Response
DIRECTOR, CHIEF EXECUTIVE OFFICER, PRESIDENT AND SECRETARY OF ISSUER
Item 3. Related Persons
Name
PAUL FRIEDMAN
Address
subscription required
Relationship(s)
Clarification of Response
DIRECTOR OF ISSUER
Item 3. Related Persons
Name
DAVID BONITA
Address
subscription required
Relationship(s)
Clarification of Response
DIRECTOR OF ISSUER
Item 3. Related Persons
Name
KELVIN NEU
Address
subscription required
Relationship(s)
Clarification of Response
DIRECTOR OF ISSUER
Item 3. Related Persons
Name
JUAN LUENGO
Address
subscription required
Relationship(s)
Clarification of Response
VICE PRESIDENT OF ISSUER
Item 4. Industry Group
BIOTECHNOLOGY
Item 5. Issuer Size
Revenue Range (for issuer not specifying "hedge" or "other investment" fund in Item 4 above)
DECLINE TO DISCLOSE
Item 6. Federal Exemptions and Exclusions Claimed
Item 7. Type of Filing
Amendment
Date of First Sale in this Offering:
10/06/2017
Item 8. Duration of Offering
Does the issuer intend this offering to last more than one year?
No
Item 9. Type(s) of Securities Offered
Item 10. Business Combination Transaction
Is this offering being made in connection with a business combination
transaction, such as a merger, acquisition or exchange offer?
No
Clarification of Response
Item 11. Minimum Investment
Minimum Investment accepted from any outside investor
0
Item 13. Offering and Sales Amounts
Total Offering Amount
29999998
Total Amount Sold
29999998
Total Remaining to be Sold
0
Clarification of Response
Item 14. Investors
Securities in the offering have been or may be sold to persons
who do not qualify as accredited investors,
Number of non-accredited investors who already have invested in the offering:
Total number of investors who already have invested in the offering:
7
Item 15. Sales Commissions and Finders' Fees Expenses
Sales Commissions:
0.0
Finders' Fees
0.0
Clarification of Response
Item 16. Use of Proceeds
Provide the amount of the gross proceeds of the offering
that has been or is proposed to be used for payments to any of the persons required
to be named as executive officers,directors or promoters in response to Item 3 above.
0.0
Clarification of Response
Signature and Submission
Issuer Name
PRELUDE THERAPEUTICS INC
Issuer Signature
/S/ KRISHNA VADDI
Signer Name
KRISHNA VADDI
Signer Title
CHIEF EXECUTIVE OFFICER
Signature Date
08/16/2018